[The effects of gastrojejunostomy for patients with advanced gastric cancer accompanied by peritoneal dissemination]

Gan To Kagaku Ryoho. 2010 Nov;37(12):2279-81.
[Article in Japanese]

Abstract

We evaluated the efficacy of gastrojejunostomy for advanced gastric cancer patients with peritoneal dissemination.

Patients and methods: We evaluated the clinical outcome of 11 patients (average age 73.5 years for 8 men) who received gastrojejunostomy for gastric outlet obstruction caused by advanced gastric cancer with peritoneal dissemination between October 2003 and December 2008. We performed stomach-partitioning gastrojejunistomy with tube jejunostomy.

Results: Three patients with performance status 3 and severe peritoneal dissemination deteriorated during the early postoperative days and were transferred to terminal care. These three patients died after 23, 26 and 60 days. The other 8 patients were discharged from hospital between 10 and 35 days postoperatively (median hospital stay 16 days) and received chemotherapy with S-1 on an outpatient basis. All patients died within one year except the one who showed a partial response to chemotherapy and lived for 40 months (MST: 8 months in all patients).

Discussion: It seemed that there was little adaptation to gastrogejunostomy as palliation surgery for patients with poor performance status (PS 3) and severe peritoneal dissemination.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / therapeutic use
  • Drug Combinations
  • Female
  • Gastric Bypass*
  • Gastric Outlet Obstruction / surgery
  • Humans
  • Male
  • Middle Aged
  • Oxonic Acid / therapeutic use
  • Palliative Care
  • Peritoneal Neoplasms / secondary*
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / pathology*
  • Stomach Neoplasms / surgery*
  • Tegafur / therapeutic use
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid